DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA A

专利名称：DIAGNOSTIC PROBES AND THERAPEUTICS

TARGETING uPA AND uPAR

发明人：MAZAR, Andrew, P.,JONES, Terence, R.申请号：EP00970496.6申请日：20000927公开号：EP1218496A2公开日：20020703

摘要：A uPAR-targeting protein or peptide is diagnostically or therapeutically labeledand used in methods of diagnosis of therapy. The labeled protein or peptide preferablyhas the following properties: it comprises at least 38 amino acid residues, includingresidues 13-30 of the uPAR-binding site of uPA; competes with labeled DFP-uPA forbinding to a cell or molecule that has a binding site for uPA, and has an IC50 value ofabout 10 nM or less; and is not a fusion protein wherein the uPA peptide is fused toanother non-uPA protein or peptide. Preferred molecules are uPA, scuPA, tcuPA, an N-terminal fragment of uPA, residues 1-135, an N-terminal fragment of uPA, residues 1-143,an N-terminal fragment of uPA, residues 1-43; or an N-terminal fragment of uPA,residues 4-43. Detectable labels include a radionuclide, a PET-imageable agent, an MRI-imageable agent, a fluorescer, a fluorogen, a chromophore, a chromogen, a

phosphorescer, a chemiluminescer or a bioluminescer. The disclosed methods are usedto inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or to induceapoptosis, preferably in the treatment of a subject having a disease or conditionassociated with undesired cell migration, invasion, proliferation or angiogenesis.

申请人：Angstrom Pharmaceuticals, inc.

地址：Suite 105,6310 Nancy Ridge Drive San Diego, CA 92121 US

国籍：US

代理机构：Wright, Simon Mark

更多信息请下载全文后查看